The Human Papillomavirus (HPV) Testing Market is growing as the healthcare industry places more importance on early detection and prevention of HPV-related cancers. A recent global estimate places the market at USD 4.6 billion in 2025, with expected growth to USD 9.24 billion by 2035 at a 7.3% CAGR.

The industry is moving toward more sensitive and automated molecular testing solutions. DNA testing remains a major segment, while HPV mRNA testing, genotyping, multiplex assays, and automated molecular systems are supporting more detailed and efficient screening workflows.

HPV testing is primarily used for cervical cancer screening and follow-up, with applications also extending to cervical cancer triage, anal cancer screening, and other HPV-associated cancers. Hospitals, diagnostic laboratories, clinics, and public health screening programs form the main end-user groups.

North America and Europe have strong demand due to developed screening infrastructure and widespread use of molecular diagnostics. Meanwhile, Asia-Pacific and other emerging regions provide considerable opportunities as governments expand preventive healthcare and improve access to HPV screening.

The market has strong potential for self-sampling kits, rapid molecular testing, AI-supported screening workflows, and connected diagnostic platforms. These innovations could help healthcare systems increase screening participation and provide more efficient pathways for identifying high-risk HPV infections.